Lin Luo

Dr. Lin Luo


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2021 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
LLLin Luo
Lin Luo
XHXianzhen Hu
Xianzhen Hu
MDMichael L. Dixon
Michael L. Dixon
BPBrandon J. Pope
Brandon J. Pope
JLJonathan D. Leavenworth
Jonathan D. Leavenworth
Jianmei W. LeavenworthJianmei W. Leavenworth
Jianmei W. Leavenworth
Background: Follicular regulatory T (TFR) cells are essential for the regulation of germinal center (GC) response and humoral self-tolerance. Dysregulated follicular helper T (TFH) cell-GC-antibody (Ab) response secondary to dysfunctional TFR cells is the root of an array of autoimmune disorders. The contribution of TFR cells to the pathogenesis of multiple sclerosis (MS) and murine experimental autoimmune encephalomyelitis (EAE) remains largely unclear. Methods: To determine the impact of dysregulated regulatory T cells (Tregs), TFR cells, and Ab responses on EAE, we compared the MOG-induced EAE in mice with a FoxP3-specific ablation of the transcription factor Blimp1 to control mice. In vitro co-culture assays were used to understand how Tregs and Ab regulate the activity of microglia and central nervous system (CNS)-infiltrating myeloid cells. Results: Mice with a FoxP3-specific deletion of Blimp1 developed severe EAE and failed to recover compared to control mice, reflecting conversion of Tregs into interleukin (IL)-17A/granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing effector T cells associated with increased TFH-Ab responses, more IgE deposition in the CNS, and inability to regulate CNS CD11b+ myeloid cells. Notably, serum IgE titers were positively correlated with EAE scores, and culture of CNS CD11b+ cells with sera from these EAE mice enhanced their activation, while transfer of Blimp1-deficient TFR cells promoted Ab production, activation of CNS CD11b+ cells, and EAE. Conclusions: Blimp1 is essential for the maintenance of TFR cells and Ab responses in EAE. Dysregulated TFR cells and Ab responses promote CNS autoimmunity.

1 May 2020 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
LLLin Luo
Lin Luo
GZGaoshan Zhang
Gaoshan Zhang
LMLiuliu Mao
Liuliu Mao
PWPengbo Wang
Pengbo Wang
CXChenghao Xi
Chenghao Xi
Jianmei W. LeavenworthJianmei W. Leavenworth
Jianmei W. Leavenworth

2 June 2025 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
YZYinwei Zhou
Yinwei Zhou
WWWenbo Wang
Wenbo Wang
HGHan Gu
Han Gu
江江江颖 江
江颖 江
XWXi Wang
Xi Wang
LLLin Luo
Lin Luo

18 October 2024 in International Immunopharmacology
Verified
Journal Article
Closed access
LZLianqi Zhao
Lianqi Zhao
TLTingting Li
Tingting Li
YZYinwei Zhou
Yinwei Zhou
PWPengbo Wang
Pengbo Wang
LLLin Luo
Lin Luo

1 February 2017 in Experimental and Toxicologic Pathology
Verified
Journal Article
Closed access
LLLin Luo
Lin Luo
TXTingting Xu
Tingting Xu
PWPengbo Wang
Pengbo Wang
LMLiuliu Mao
Liuliu Mao
CXChenghao Xi
Chenghao Xi
WZWei Zhang
Wei Zhang

1 January 2024 in International Journal of Immunopathology and Pharmacology
Verified
Journal Article
Open access
LXLing Xu
Ling Xu
YJYing Jiang
Ying Jiang
FXFuping Xu
Fuping Xu
JLJun Liu
Jun Liu
YJYuhong Jiang
Yuhong Jiang
LLLin Luo
Lin Luo
Introduction: TYK2 inhibitors and traditional natural drugs as promising drugs for psoriasis therapy are receiving increasing attention. They both affect different molecules of JAK/STAT pathway, but it is currently unclear whether their combination will enhance the effect on psoriasis. In this study, we used imiquimod (IMQ)-induced psoriasis mouse model to investigate the therapeutic effects of the combined administration of deucravacitinib (TYK2 inhibitor) and shikonin.Methods: Aldara cream containing 5% IMQ was used to topically treat the dorsal skin of each mouse for a total of six consecutive days to induce psoriasis. The psoriasis area and severity index (PASI) scores were recorded every day. On the 7thday, skin tissues were taken for histopathological examination and the content of cytokines in skin were evaluated. The frequency of immune cells in peripheral blood, spleen and skin were detected through flow cytometry.Results: Compared to the vehicle control group, the psoriasis symptoms and immune disorder improved significantly in the combination therapy group and deucravacitinib treatment group on the 7th day, and the expressions of p-STAT3 and Ki67 in skin were reduced as well. Moreover, the combined treatment of deucravacitinib and shikonin for psoriasis was superior to the monotherapy group, especially in inhibiting abnormal capillaries proliferation, reducing immune cells infiltration and decreasing the concentration of IL-12p70 in skin.Conclusion: The combination of deucravacitinib and shikonin is a promising clinical application.